Loading...
| A03467 | Pages: NA | Dec 2021 | 5527 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Diclofenac Market
Request Now !Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) that is mainly employed to treat mild-to-moderate pain & reduces pain, inflammation, swelling, and stiffness. This drug is applicable for inflammatory disorders such as arthritis, rheumatoid arthritis, dermatomyositis, osteoarthritis, dental pain, spondylarthritis, and gout attacks.
The major factors that contribute to the growth of the diclofenac market include increasing prevalence of autoimmune and respiratory conditions such as arthritis & dental pain, increasing adoption of anti-inflammatory drugs, growing awareness about anti-inflammatory therapeutics, development in R&D activities, and attractive government initiatives in emerging countries.
However, side effects of anti-inflammatory drugs and patent expiry issues of drugs may impede the market growth. High demand for better and novel anti-inflammatory therapeutics with lesser side effects & better efficacy are expected to provide numerous opportunities for market growth during the forecast period.
The diclofenac market is segmented on the basis of indication, route of administration, and region. According to indication, the market is divided into osteoarthritis, ankylosing spondylitis, dysmenorrhea, rheumatoid arthritis, migraine, pain, and others. On the basis of formulation, the market is segmented into oral and parenteral. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players that operate in this market include Auro Laboratories Limited, Henan Dongtai Pharmaceutical Co., Bayer AG, Pfizer Inc., Hunan Warrant Pharmaceutical Co., Ltd, Novartis AG, XianShi Pharmaceutical Group, Merck & Co., Inc., Istituto Biochimico Italiano G. Lorenzini S.p.A., and Dezhou Deyao Pharmaceutical Co., Ltd.
Key Benefits
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.5. MARKET DYNAMICS
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
CHAPTER 4 DICLOFENAC MARKET, BY INDICATION
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. OSTEOARTHRITIS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. ANKYLOSING SPONDYLITIS
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. DYSMENORRHEA
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. RHEUMATOID ARTHRITIS
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. MIGRAINE
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
4.7. PAIN
4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast
4.8. OTHERS
4.8.1. Key market trends
4.8.2. Growth factors and opportunities
4.8.3. Market size and forecast
CHAPTER 5 DICLOFENAC MARKET, BY FORMULATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. ORAL
5.2.1. Market size and forecast
5.3. PARENTERAL
5.3.1. Market size and forecast
CHAPTER 6 DICLOFENAC MARKET, BY REGION
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Diclofenac Market by Indication
6.2.5. North America Diclofenac Market by Formulation
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Diclofenac Market by Indication
6.3.5. Europe Diclofenac Market by Formulation
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Diclofenac Market by Indication
6.4.5. Asia-Pacific Diclofenac Market by Formulation
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Saudi Arabia market size and forecast
6.5.3.3. South Africa market size and forecast
6.5.3.4. Rest of LAMEA market size and forecast
6.5.4. LAMEA Diclofenac Market by Indication
6.5.5. LAMEA Diclofenac Market by Formulation
CHAPTER 7 COMPANY PROFILES
7.1. AURO LABORATORIES LIMITED
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. HENAN DONGTAI PHARMACEUTICAL CO.
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. BAYER AG
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. PFIZER INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. HUNAN WARRANT PHARMACEUTICAL CO., LTD.
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. NOVARTIS AG
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. XIANSHI PHARMACEUTICAL GROUP
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. MERCK & CO., INC.
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. ISTITUTO BIOCHIMICO ITALIANO G. LORENZINI S.P.A.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. DEZHOU DEYAO PHARMACEUTICAL CO., LTD.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
10%
Discount
10%
Discount
10%
Discount
10%
Discount
Enterprise
License/PDF
10%
Discount
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
